[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2] QI J,LI M,WANG L,et al.National and subnational trends in cancer burden in China,2005-20:an analysis of national mortality surveillance data［J］.Lancet Public Health,2023,8(12):e943-e955.
[3] XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants［J］.Chin Med J(Engl),2022,135(5):584-590.
[4] LIU X,YUC,BI Y,et al.Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China［J］.Public Health,2019,172:70-80.
[5] KC M,FAN J,HYSLOP T,et al.Relative burden of cancer and noncancer mortality among long-term survivors of breast,prostate,and colorectal cancer in the US［J］.JAMA Netw Open,2023,6(7):e2323115.
[6] HELLMAN S,WEICHSELBAUM RR.Oligometastases［J］.J Clin Oncol,1995,13(1):8-10.
[7] KATARIA T,NAGA P,BANERJEE S,et al.CyberKnife stereotactic ablative radiotherapy for recurrent or oligometastatic gynecological cancers［J］.South Asian J Cancer,2021,10(2):107-111.
[8] WANG XS,BAI YF,VERMA V,et al.Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer［J］.J Natl Cancer Inst,2023,115(6):742-748.
[9] MESKO SHANE,SANDLERKIRI,COHEN JOSHUA,et al.Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies［J］.Int J Gynecol Cancer,2017,(2):403-408.
[10] UPPAL ABHINEET,FERGUSON MARK K,POSNER MITCHELL C,et al.Towards a molecular basis of oligometastatic disease:potential role of micro-RNAs［J］.Clin Exp Metastasis,2014,31(6):735-748.
[11] DEEK MP,VAN DER EECKEN K,PHILLIPS R,et al.The mutational landscape of metastatic castration-sensitive prostate cancer:The spectrum theory revisited［J］.Eur Urol,2021,80(5):632-640.
[12] OKA R,UTSUMI T,NORO T,et al.Progress in oligometastatic prostate cancer:Emerging imaging innovations and therapeutic approaches［J］.Cancers(Basel),2024,16(3):507.
[13] MAHJOUB S,HEIDENREICH A.Oligometastatic prostate cancer:definition and the role of local and systemic therapy:a narrative review［J］.Transl Androl Urol,2021,10(7):3167-3175.
[14] CAHILL EM,PFAIL JL,FU MZ,et al.Metastasis-directed therapy for oligometastatic castration-sensitive prostate cancer:An alternative to ADT［J］.Curr Urol Rep,2023,24(7):299-306.
[15] ALUWINISHAFAKS,MEHRANIVEN,LOLKEMA MARTIJN P,et al.Oligometastatic prostate cancer:Results of a dutch multidisciplinary consensus meeting［J］.Eur Urol Oncol,2020,3(2):231-238.
[16] GILLESSENSILKE,ATTARDGERHARDT,BEER TOMASZ M,et al.Management of patients with advanced prostate cancer:Report of the advanced prostate cancer consensus conference 2019［J］.Eur Urol,2020,77(4):508-547.
[17] GANDAGLIAGIORGIO,KARAKIEWICZ PIERRE I,BRIGANTI ALBERTO,et al.Impact of the site of metastases on survival in patients with metastatic prostate cancer［J］.Eur Urol,2015,68(2):325-334.
[18] KHOO V.New concepts in prostate cancer management:the conundrum of managing oligometastatic disease in prostate cancer-through the looking glass darkly［J］.Clin Radiol,2019,74(11):865-875.
[19]JENJITRANANT P,TOUIJER KA.Role of surgery in oligometastatic prostate cancer［J］.Prostate Int,2019,7(4):125-130
[20] GUCKENBERGER M,LIEVENS Y,BOUMA AB,et al.Characterisation and classification of oligometastatic disease:a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation［J］.Lancet Oncol,2020,21(1):e18-e28.
[21] DESOUZA NANDITA M,TEMPANY CLARE M.A risk-based approach to identifying oligometastatic disease on imaging［J］.Int J Cancer,2019,144(3):422-430.
[22] ALBALOOSHI B,AL SHARHAN M,BAGHERI F,et al.Direct comparison of 99Tcm-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer［J］.Asia Ocean J Nucl Med Biol,2020,8(1):1-7.
[23] STEFAN AK,KATHARINA S,CLEMENS,et al.Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer［J］.Eur J Nucl Med Mol Imaging,2021,48(1):143-151.
[24] MICHAEL MCCARTHY,ROSLYN FRANCIS,COLIN TANG,et al.A multicenter prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma:Oligometastatic rate and distribution compared with standard imaging［J］.Int J Radiat Oncol Biol Phys,2019,104(4):801-808.
[25] UDOVICICH C,PERERA M,HOFMAN MS,et al.68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer:Current state and future trends［J］.Prostate International,2017,5(4):125-129.
[26] GUPTA SK,WATSON T,DENHAM J,et al.Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer distribution of disease and implications for radiation therapy planning［J］.Int J Radiat Oncol Biol Phys,2017,99(3):701-709.
[27] ZILLI T,ACHARD V,DAL PRA A,et al.Recommendations for radiation therapy in oligometastatic prostate cancer:An ESTRO-ACROP Delphi consensus［J］.Radiother Oncol,2022,176:199-207.
[28] ROGOWSKI P,TRAPP C,VON BESTENBOSTEL R,et al.Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology(DEGRO)［J］.Strahlenther Onkol,2022,198(8):727-734.
[29] KUNATH F,BORGMANN H,BLUMLE A,et al.Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis［J］.Bmj Open,2015,5(11):e008217-e008217.
[30] GARJE R,CHENNAMADHAVUNI A,MOTT SL,et al.Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer［J］.Clin Genitourin Cancer,2020,18(2):e157-e166.
[31]GROSSMANN M,CHEUNG AS,ZAJAC JD.Androgens and prostate cancer:pathogenesis and deprivation therapy［J］.Best Pract Res Clin Endocrinol Metab,2013,27(4):603-616.
[32] HUSSAIN M,T ANGEN C,HIGANO C,et al.Evaluating intermittent androgen-deprivation therapy phase III clinical trials:The devil is in the details［J］.J Clin Oncol,2016,34(3):280-285.
[33] KYRIAKOPOULOS CE,CHEN YH,CARDUCCI MA,et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer:Long-term survival analysis of the randomized phase III E3805 CHAARTED trial［J］.J Clin Oncol,2018,36(11):1080-1087.
[34] CLARKE NW,ALI A,INGLEBY FC,et al.Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer:long-term survival results from the STAMPEDE trial［J］.Ann Oncol,2019,30(12):1992-2003.
[35] CHI KN,AGARWAL N,BJARTELL A,et al.Apalutamide for metastatic,castration-sensitive prostate cancer［J］.N Engl J Med,2019,381(1):13-24.
[36] ARMSTRONG AJ,SZMULEWITZ RZ,PETRYLAK DP,et al.ARCHES:A randomized,phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer［J］.J Clin Oncol,2019,37(32):2974-2986.
[37] TZELEPI V,EFSTATHIOU E,WEN S,et al.Persistent,biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment［J］.J Clin Oncol,2011,29(18):2574-2581.
[38] DEEK MP,PHILLIPS RM,TRAN PT.Local therapies in oligometastatic and oligoprogressive prostate cancer［J］.Semin Radiat Oncol,2021,31(3):242-249.
[39] HEIDENREICH A,PFISTER D,PORRES D.Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases:results of a feasibility and case-control study［J］.J Urol,2015,193(3):832-838.
[40] DAI B,ZHANG S,WAN FN,et al.Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer:A phase II randomized controlled trial［J］.Eur Urol Oncol,2022,5(5):519-525.
[41] CHENG B,YE S,BAI P.The efficacy of cytoreductive surgery for oligometastatic prostate cancer:a meta-analysis［J］.World J Surg Oncol,2021,19(1):160.
[42] MAO Y,HU M,YANG G,et al.Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases:a systematic meta-analysis［J］.World J Surg Oncol,2022,20(1):255.
[43] PREZIOSO D,LOTTI T,POLITO M,et al.Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate,before radical prostatectomy:a randomized study［J］.Urol Int,2004,72(3):189-195.
[44]YEE DS,LOWRANCE WT,EASTHAM JA,et al.Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial［J］.BJU Int,2010,105(2):185-190.
[45] ANTONINO,BATTAGLIA,GERT,et al.Novel insights into the management of oligometastatic prostate cancer:A comprehensive review［J］.EurUrol Oncol,2019,2(2):174-188.
[46] JENJITRANANT P,TOUIJER KA.Role of surgery in oligometastatic prostate cancer［J］.Prostate Int,2019,7(4):125-130.
[47] MISZCZYK M,RAJWA P,YANAGISAWA T,et al.The efficacy and safety of metastasis-directed therapy in patients with prostate cancer:A systematic review and Meta-analysis of prospective studies［J］.Eur Urol,2024,85(2):125-138.
[48] PARKER CC,JAMES ND,BRAWLEY CD,et al.Radiotherapy to the primary tumour for newly diagnosed,metastatic prostate cancer(STAMPEDE):a randomised controlled phase 3 trial［J］.Lancet,2018,392(10162):2353-2366.
[49] BOEVE LMS,HULSHOF M,VIS AN,et al.Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial:Data from the HORRAD trial［J］.Eur Urol,2019,75(3):410-418.
[50] BURDETT S,BOEVE LM,INGLEBY FC,et al.Prostate radiotherapy for metastatic hormone-sensitive prostate cancer:A STOPCAP systematic review and Meta-analysis［J］.Eur Urol,2019,76(1):115-124.
[51] PARKER CC,JAMES ND,BRAWLEY CD,et al.Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland:Long-term results from the STAMPEDE randomised controlled trial［J］.PLoS Med,2022,19(6):e1003998.
[52] ONAL C,KOSE F,OZYIGIT G,et al.Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment［J］.Prostate,2021,81(9):543-552.
[53] OST P,REYNDERS D,DECAESTECKER K,et al.Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence:A prospective,randomized,multicenter phase II trial［J］.J Clin Oncol,2018,36(5):446-453.
[54] FRANCOLINI G,ALLEGRA AG,DETTI B,et al.Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer:A randomized phase II trial(ARTO)［J］.J Clin Oncol,2023,41(36):5561-5568.
[55] CORNFORD P,VAN DEN BERGH RCN,BRIERS E,et al.EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer.Part II-2020 update:Treatment of relapsing and metastatic prostate cancer［J］.Eur Urol,2021,79(2):263-282.
[56] GILLESSEN S,BOSSI A,DAVIS ID,et al.Management of patients with advanced prostate cancer.Part I:Intermediate-/high-risk and locally advanced disease,biochemical relapse,and side effects of hormonal treatment:Report of the advanced prostate cancer consensus conference 2022［J］.Eur Urol,2023,83(3):267-293.
[57]PILEPICH MV,WINTER K,JOHN MJ,et al.Phase III radiation therapy oncology group(RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate［J］.Int J Radiat Oncol Biol Phys,2001,50(5):1243-1252.
[58]JONES CU,HUNT D,MCGOWAN DG,et al.Radiotherapy and short-term androgen deprivation for localized prostate cancer［J］.N Engl J Med,2011,365(2):107-118.
[59]STANISZEWSKA M,IKING J,LUCKERATH K,et al.Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer［J］ Nucl Med Biol,2021,97:101-111.
[60]HYVAKKA A,VIRTANEN V,KEMPPAINEN J,et al.More than meets the eye:Scientific rationale behind molecular imaging and therapeutic targeting of prostate-specific membrane antigen(PSMA) in metastatic prostate cancer and beyond［J］.Cancers(Basel),2021,13(9):2244.
[61] BEGUM NJ,THIEME A,EBERHARDT N,et al.The effect of total tumor volume on the biologically effective dose to tumor and kidneys for Lu-labeled PSMA peptides［J］.J Nucl Med,2018,59(6):929-933.